购物车
- 全部删除
- 您的购物车当前为空
PF-06439015 overcomes clinical ALK (receptor tyrosine kinase anatropic lymphoma kinase) mutations resistant to krizotinib. Pf-06439015 is an effective selective inhibitor.
PF-06439015 overcomes clinical ALK (receptor tyrosine kinase anatropic lymphoma kinase) mutations resistant to krizotinib. Pf-06439015 is an effective selective inhibitor.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
25 mg | ¥ 16,100 | 10-14周 | |
50 mg | ¥ 21,300 | 10-14周 | |
100 mg | ¥ 27,500 | 10-14周 |
产品描述 | PF-06439015 overcomes clinical ALK (receptor tyrosine kinase anatropic lymphoma kinase) mutations resistant to krizotinib. Pf-06439015 is an effective selective inhibitor. |
别名 | PF-06439015, PF06439015, PF 06439015 |
分子量 | 470.52 |
分子式 | C22H23FN6O3S |
CAS No. | 1549629-82-4 |
密度 | 1.47 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容